# US 2025/0152671 A1 · Medical composition for treating patients exhibiting cardiac decompensation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152671 A1
- Document ID: US20250152671A1
- Status: Published application
- Kind: A1
- Application number: 19/013,221
- Filed: 2025-01-08
- Published: 2025-05-15
- Earliest claimed: 2019-11-16
- Assignees: RELAXERA Pharmazeutische GmbH & Co. KG
- Applicants: RELAXERA Pharmazeutische GmbH & Co. KG
- Inventors: Thomas Bernd DSCHIETZIG
- Web page: https://patentgrep.com/patent/US20250152671A1

## CPC

- A61K 38/2221: {Relaxins}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject exhibiting cachexia syndrome or cardiac wasting or cardiac decompensation. The application also describes methods of treating cachexia, cardiac wasting and patients exhibiting clinical signs of suffering from cardiac decompensation. Further described is a method of using a patch pump for subcutaneous or intravenous infusion of relaxin or human relaxin-2.

## Claims

### Claim 1

A method of treating a subject exhibiting clinical signs of cardiac decompensation comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.

### Claim 2

A method of treating a subject exhibiting clinical signs of cardiac decompensation when those signs are manifested as dyspnoea or congestion, comprising the administration of an effective amount of human relaxin-2, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.

### Claim 3

A method of treating hospice patients exhibiting clinical signs of cardiac decompensation comprising the administration of relaxin-2 to improve their clinical status, wherein said method comprises administering synthetic human relaxin-2 at 10 to 100 μg relaxin-2/kg body weight/day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is further diagnosed having a sustained ventricular tachycardia of greater than 80 to 100 bpm and/or having an increased resting heart rate of greater than 80 bpm and/or having elevated levels of troponin in blood or serum or plasma which is greater than the 90th percentile of a standard normal distribution and/or an N-terminal prohormone B-type natriuretic peptide (NTproBNP) level in blood or serum or plasma which is greater than 1000 pg/ml.

### Claim 5 (depends on 1)

The method of claim 1, which comprises administering synthetic human relaxin-2 at 25 μg/kg body weight/day. 6 The method of claim 1, which comprises subcutaneous or intravenous infusion of human relaxin-2 at a rate of 10 to 100 μg/kg body weight/day.

### Claim 7 (depends on 1)

The method of claim 1, which comprises subcutaneous or intravenous infusion of human relaxin-2 at a rate of 10 to 100 μg/kg body weight/day.

### Claim 8 (depends on 1)

The method of claim 1, which comprises administering said human relaxin-2 with a patch pump prefilled with a pharmaceutical composition suitable for subcutaneous or intravenous infusion of human relaxin-2 at a rate of 10 to 250 μg/kg body weight/day.
